Compare ZSQR & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZSQR | DRUG |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 697.4M | 778.4M |
| IPO Year | 2020 | 2020 |
| Metric | ZSQR | DRUG |
|---|---|---|
| Price | $3.65 | $77.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $129.25 |
| AVG Volume (30 Days) | ★ 341.1K | 176.6K |
| Earning Date | N/A | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.27 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,363,045.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.71 | $38.00 |
| 52 Week High | $16.62 | $123.75 |
| Indicator | ZSQR | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 30.57 | 52.92 |
| Support Level | N/A | $76.54 |
| Resistance Level | $4.20 | $83.65 |
| Average True Range (ATR) | 0.44 | 3.86 |
| MACD | 0.22 | -0.01 |
| Stochastic Oscillator | 3.33 | 37.03 |
Z Squared Inc is a computing infrastructure company operating computing equipment and expanding into AI infrastructure. The Company's idea is to build on three principles: guide with power by acquiring operating sites where power is already flowing; build for AI workloads by converting that capacity into AI-ready colocation where the customer brings the compute and runs what it needs; and scale with discipline by deploying conversion capital site by site, against signed contracts and operational readiness.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.